NCT03537482View on ClinicalTrials.gov

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 7, 2018

Primary Completion Date

September 15, 2024

Study Completion Date

February 15, 2025

Conditions
Hematologic Malignancies
Interventions
DRUG

APG-2575

APG-2575 will be administered as an oral tablet

Trial Locations (5)

3065

RECRUITING

St. Vincent Hospital, Fitzroy

3121

RECRUITING

Epworth Healthcare, Richmond

27701

COMPLETED

Duke Unviersity, Durham

32224

RECRUITING

Mayo Clinic, Jacksonville

77030

RECRUITING

MDACC, Houston

Sponsors
All Listed Sponsors
lead

Ascentage Pharma Group Inc.

INDUSTRY

NCT03537482 - APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Biotech Hunter | Biotech Hunter